drugset / Trial / NCT00449670

Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults

NCT00449670

Phase 3 Completed 1206 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelPrevention

Summary

The present study is designed to assess the lot-to-lot consistency of the immunogenicity of a GlaxoSmithKline Biologicals' pandemic influenza candidate vaccine (GSK1562902A) in adults aged between 18 and 60 years.

Timeline

Start
2007-03-24
Primary completion
2007-07-12
Completion
2008-06-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK1562902A Vaccine Intramuscular
Subject GSK1562902A Vaccine

Indications